Starpharma appoints further VP Business Development to meet increasing demand for its technology

Starpharma appoints further VP Business Development to meet increasing demand for its technology

Melbourne Australia; 12 July 2010: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced it has appointed Malcolm McColl to join the company's existing business development team as a Vice President to meet the growing market demand for pharmaceutical and life science applications of Starpharma's dendrimer technology, particularly in drug delivery.

Malcolm is a seasoned business development professional with more than 20 years' experience with major biotechnology companies, including 13 years with CSL where he negotiated major agreements with Pfizer and Bayer, amongst many others. Malcolm joins Starpharma in August in the role of VP Business Development and will be supporting and enhancing Starpharma's already successful partnering activities and programs.

Malcolm returns to Australia from the UK where as Hospira's Business Development Director, Europe Middle East and Africa (EMEA), he was responsible for growing the global and EMEA business through an ambitious plan of targeted acquisitions and licensing activities. There he led negotiations and due diligence for a significant number of license agreements and transactions including Hospira's recent ~A$135M deal with Chemgenex for rights to Omacetaxine, a proprietary oncology product.

Dr Jackie Fairley, Chief Executive Officer of Starpharma, welcomed Malcolm to the executive team: "We are delighted to have Malcolm join Starpharma at this exciting stage of the company's development. His contribution will further enhance our already highly successful partnering activities in drug delivery, VivaGel®, in vitro diagnostics (IVD) and agrochemicals. Malcolm's international industry networks and experience will be a great asset in securing further commercial agreements and with this additional business development resource, Starpharma will significantly boost its commercial development capabilities." Starpharma has established a successful business model of partnering with marketleading companies to maximise the value of its dendrimer platform in a range of industries and applications. The company has a growing list of major companies that are actively exploring the use of Starpharma's proprietary dendrimer technology to enhance the performance their pharmaceutical products, including Lilly, GSK, and in animal health, Elanco.

The company also has established commercial relationships with leading companies, such as SSL International plc, Siemens Healthcare, and EMD Merck KgA for other applications of its proprietary dendrimer technology.

About Starpharma Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA.

Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

Page 2 of 2 The Company's lead pharmaceutical development product is VivaGel® (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

In the wider pharmaceutical field Starpharma has specific programs in the areas of Drug Delivery and Drug Optimisation technologies (using dendrimers to control where and when drugs go when introduced to the body) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signalling and targeting groups are added to allow location of specific cell type, such as cancer cells). More broadly the company is exploring dendrimer opportunities in materials science with applications as diverse as adhesives, lubricants and water remediation.

SPL has a comprehensive IP portfolio that comprises more than 224 patents/applications issued and pending across 56 patent families - a unique level of IP concentration among nanotechnology companies.

Dendrimers: A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

American Depositary Receipts (ADRs): Starpharma's ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Securities Exchange (ASX). The Bank of New York Mellon is the depositary bank. Starpharma's ADRs are listed on International OTCQX (otcqx.com), a premium market tier in the U.S. for international exchange-listed companies, operated by Pink OTC Markets, Inc.

Forward Looking Statements This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.

There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

For further information: Media Buchan Consulting Starpharma www.starpharma.com Rebecca Wilson Mob: +61 417 382 391 [email protected] Jessica Sealby Tel: +61 3 9866 4722 [email protected] Dr Jackie Fairley Chief Executive Officer +61 3 8532 2704 Ben Rogers Company Secretary +61 3 8532 2702 [email protected]
 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.